To investigate the potential formation of new-born SOM+ interneurons, we treated mice with the thymidine analog BrdU for 2 weeks after stroke and assessed the number of double positive SOM+/BrdU+ cells 6 weeks thereafter. This evidence concerns the gene GRHL3 and stroke disorder.